<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market growthDublin, Aug. 26, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6262676/mrna-therapeutics-market-target-indication-non?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=km2tz5&amp;utm_campaign=2338001+-+mRNA+Therapeutics+Market+Outlook+Report+2026-2035+Featuring+Profiles+of+Arcturus+Therapeutics%2c+BioNTech%2c+CureVac%2c+Moderna%2c+Providence+Therapeutics%2c+RNAimmune%2c+Recode+Therapeutics%2c+and+More&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035">"mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035"</a> has been added to ResearchAndMarkets.com's offering. The global mRNA therapeutics market for applications beyond COVID-19 is estimated to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, reflecting a compound annual growth rate of approximately 63% during the forecast period. Growth is being supported by expanding clinical pipelines, increasing investment, advances in lipid nanoparticle delivery, and rising demand for precision therapies across oncology, rare genetic diseases, cardiovascular disorders, autoimmune conditions, and regenerative medicine. mRNA Therapeutics Market Growth and Trends Messenger RNA (mRNA) therapeutics have emerged as an important biopharmaceutical platform with potential applications across multiple disease areas. The platform's modularity allows developers to adapt RNA constructs for different therapeutic targets while using established manufacturing and delivery processes, potentially reducing development timelines. Oncology remains a major focus for mRNA drug development. Investigational candidates are being designed to encode tumor-associated antigens, patient-specific neoantigens, and immune-stimulatory proteins. These therapies are increasingly being evaluated in combination with checkpoint inhibitors and other immuno-oncology treatments. In rare genetic diseases, mRNA-based protein replacement candidates may help restore missing or dysfunctional proteins through repeat dosing without introducing permanent genetic changes. Market participants are also pursuing greater vertical integration by internalizing RNA construct optimization, manufacturing, and delivery capabilities. This approach can shorten development cycles, strengthen intellectual property positions, and improve control over supply chains. Strategic alliances between biotechnology companies and major pharmaceutical manufacturers are further supporting clinical development and commercialization. Key Market Growth Drivers The increasing global burden of cancer, rare genetic disorders, and autoimmune diseases is creating demand for targeted and differentiated therapies. Advances in genomics, biomarker discovery, molecular diagnostics, and next-generation sequencing are strengthening the role of mRNA therapeutics in precision medicine. Government funding, venture capital investment, and pharmaceutical partnerships are also accelerating market expansion. Investment is increasingly directed toward RNA manufacturing infrastructure, tissue-selective delivery systems, non-lipid nanoparticle technologies, and repeat-dose formulations. Collaborations between emerging biotechnology developers and established pharmaceutical companies are helping reduce clinical and commercial risk while extending geographic reach. Challenges Affecting mRNA Therapeutics Development Despite strong momentum, the market faces technical, regulatory, and commercial barriers. Efficient and tissue-selective delivery beyond the liver and intramuscular compartments remains a significant development challenge. Repeat-dose tolerability, cold-chain requirements, advanced manufacturing processes, and comparatively high production costs may also affect reimbursement and market access. Regulatory pathways for chronic and repeat-dosing mRNA therapeutics continue to evolve across major jurisdictions. Intellectual property activity involving RNA constructs, lipid nanoparticles, delivery technologies, and manufacturing processes is creating additional freedom-to-operate considerations, particularly for smaller developers. Transparent stakeholder communication will remain important as the industry addresses public scrutiny surrounding mRNA-based medicines. Key mRNA Therapeutics Market Insights <ul><li>Biotechnology companies and large pharmaceutical manufacturers are prioritizing mRNA drug development across oncology and rare disease indications.</li><li>Approximately 70% of reported pipeline activity is concentrated among Moderna and BioNTech, highlighting the current concentration of market leadership.</li><li>More than 10% of the global mRNA therapeutics pipeline has reached Phase III development, indicating increasing clinical maturity.</li><li>In January 2026, Moderna partnered with Recordati to advance mRNA-3927, an investigational therapy for propionic acidemia, toward further development and potential commercialization.</li><li>In May 2026, Reprogram Biosciences raised USD 6 million in seed financing to support an mRNA-based in situ cell-reprogramming platform for oncology.</li><li>Patent filings covering mRNA constructs, manufacturing methods, and delivery systems have increased substantially over the past five years.</li><li>Large pharmaceutical companies are increasingly using partnerships and acquisitions to gain mRNA capabilities. Pfizer, Sanofi, and Bayer are among the active participants in this market.</li></ul> Market Segmentation and Regional Outlook The market analysis covers non-small cell lung cancer, melanoma, muscle-invasive urothelial carcinoma, propionic acidemia, and cystic fibrosis. Regional coverage includes North America, Europe, and Asia-Pacific, with country-level analysis for the US, Canada, Germany, the UK, France, Italy, Spain, China, Japan, South Korea, and Australia. Non-small cell lung cancer is projected to account for the largest target-indication share by 2035. Its position is supported by high global prevalence, substantial unmet need among patients with advanced disease, tumor heterogeneity, and growing interest in personalized neoantigen-based mRNA therapies. Wider use of next-generation sequencing and artificial intelligence-enabled biomarker discovery is expected to strengthen development opportunities in this indication. North America is expected to lead the global mRNA therapeutics market through 2035. The region benefits from established developers, clinically validated platforms, strong investment activity, and GMP-compliant manufacturing infrastructure that can support expanding oncology and rare disease pipelines. Asia-Pacific is projected to record the fastest growth during the forecast period. Biotechnology investment and government-backed initiatives in China, India, South Korea, and Japan are supporting domestic research, manufacturing expansion, and technology-transfer partnerships. Leading Companies in the mRNA Therapeutics Market <ul><li>Arcturus Therapeutics</li><li>BioNTech</li><li>CureVac</li><li>Moderna</li><li>Providence Therapeutics</li><li>Recode Therapeutics</li><li>RNAimmune, a subsidiary of Sirnaomics</li><li>Suzhou Abogen Biosciences</li><li>Turn Biotechnologies</li><li>Walvax</li></ul> Research Coverage The report provides market sizing and opportunity analysis by target indication and geography, along with sales forecasts for mRNA therapeutics. It assesses development stage, route of administration, delivery technology, sponsor type, clinical trial activity, patent trends, partnerships, funding, and recent strategic developments. Company profiles include portfolio, pipeline, management, location, company size, and key initiative data. The study also features competitive analysis, Porter's Five Forces analysis, and an assessment of the drivers, restraints, opportunities, and challenges influencing the mRNA therapeutics market. The forecasts combine top-down market assessment with bottom-up pipeline analysis and insights from industry stakeholders across Australia, Belgium, Germany, Italy, South Korea, Switzerland, the UK, and the US. Conservative, base-case, and optimistic scenarios support investment evaluation, business development, licensing, partnership planning, competitive benchmarking, and merger and acquisition screening. Additional report benefits include Excel data packs for analytical modules, up to 15% complimentary content customization, an in-depth walkthrough with the research team, and a complimentary update when the report is more than six months old. A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Arcturus Therapeutics</li><li>BioNTech</li><li>CureVac</li><li>Moderna</li><li>Providence Therapeutics</li><li>RNAimmune (subsidiary of Sirnaomics)</li><li>Recode Therapeutics</li><li>Suzhou Abogen Biosciences</li><li>Turn Biotechnologies</li><li>Walvax</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6262676/mrna-therapeutics-market-target-indication-non?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=km2tz5&amp;utm_campaign=2338001+-+mRNA+Therapeutics+Market+Outlook+Report+2026-2035+Featuring+Profiles+of+Arcturus+Therapeutics%2c+BioNTech%2c+CureVac%2c+Moderna%2c+Providence+Therapeutics%2c+RNAimmune%2c+Recode+Therapeutics%2c+and+More&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/bw81jl</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MjkzMDcxYzMtOTRlYi00ZGE4LTgxYTAtNDhkNzVhMjEzMjljLTEwMjY3MzctMjAyNi0wOC0yNi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn